Efficacy, safety and the lymphocyte subsets changes of low ‐dose IL‐2 in patients with systemic lupus erythematosus: A systematic review and meta‐analysis

ConclusionLD-IL-2 was promising and well-tolerated in treating SLE, which could promote Treg's proliferation and functional recovery. Injecting 0.5 million IU of IL-2 daily can better induce the differentiation of Treg cells and maintain immune homeostasis than injecting 1 million IU every other day.
Source: Immunity, Inflammation and Disease - Category: Allergy & Immunology Authors: Tags: REVIEW ARTICLE Source Type: research